OBJECTIVES: Botulinum toxins (BT) are a valuable treatment option for patients with post-stroke upper-limb spasticity (PS-ULS), which affects 33,000 patients in the UK. Xeomin (incobotulinum toxin A) and Botox (onabotulinum toxin A) are two BTs licensed for the treatment of PS-ULS. The treatment costs for Xeomin and Botox will depend on their real-world usage. METHODS: Dosing data were collected for patients switching from Botox to Xeomin treatment between 2007–2012 from the Mid-Yorkshire Hospitals Trust (MYHT) UK (comprised of 3 centres). The dose of each BT received per limb at each visit was extracted from the dataset for 7 visits (the 3 visits before and 4 visits after switching). List prices from the British National Formulary for different vial sizes were applied to these data to generate a simple budget impact model.  RESULTS: